For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 1,774,166 | |||
| General and administrative | 3,640,777 | |||
| Total operating expenses | 5,414,943 | |||
| Loss from operations | -5,414,943 | |||
| Interest expense | 72,659 | |||
| Loss on change in fair value of derivative liabilities | -6,312 | |||
| Loss (gain) on extinguishment of debt | 326,345 | |||
| Total other expense (income), net | 247,374 | |||
| Loss before provision for income taxes | -5,167,569 | |||
| Net loss | -5,167,569 | |||
| Basic EPS | -0.66 | |||
| Diluted EPS | -0.66 | |||
| Basic Average Shares | 7,812,264 | |||
| Diluted Average Shares | 7,812,264 | |||
ADAPTIN BIO, INC. (APTN)
ADAPTIN BIO, INC. (APTN)